Frontiers in Oncology最新文献

{"title":"Corrigendum: Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.","authors":"Si Yu Lin, Ke Jie Lu, Xiao Na Zheng, Jian Hou, Ting Ting Liu","doi":"10.3389/fonc.2025.1559194","DOIUrl":"https://doi.org/10.3389/fonc.2025.1559194","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2024.1341631.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1559194"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining conservative mastectomy: the evolution of surgical techniques.","authors":"Lorenzo Scardina, Gianluca Franceschini","doi":"10.3389/fonc.2025.1575095","DOIUrl":"10.3389/fonc.2025.1575095","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1575095"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review.","authors":"Ping Song, Yuqi Jin, Lifang Dai, Lijun Fang, Yinuo Tan","doi":"10.3389/fonc.2025.1537205","DOIUrl":"10.3389/fonc.2025.1537205","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have been extensively utilized in the treatment of various malignancies, with camrelizumab being one of the agents in this therapeutic class. In this study, we report for the first time a case of an allergic reaction to camrelizumab in a patient with nasopharyngeal carcinoma, who was successfully rechallenged after antiallergic treatment. The patient, a 62-year-old male, was diagnosed with advanced nasopharyngeal carcinoma, exhibiting cancer infiltration and multiple metastases. He underwent multiple cycles of therapy, tolerating camrelizumab, nab-paclitaxel, and nedaplatin (200 mg of camrelizumab every 3 weeks) without adverse reactions in the first four cycles. However, during the fifth cycle, after the intravenous infusion of camrelizumab, he experienced gradual onset of dizziness and chest tightness within 15 minutes (peripheral arterial oxygen saturation was approximately 94%, blood pressure was 76/42 mmHg, heart rate was 83 beats per minute, and respiratory rate was 15 breaths per minute). The camrelizumab infusion was immediately halted, and the patient was treated with intravenous dexamethasone (10 mg) combined with intramuscular diphenhydramine, calcium gluconate, and 500 ml of normal saline; his blood pressure gradually increased to 110/80 mmHg within 10 minutes, and pruritic erythematous macules appeared on his skin, particularly on the upper limbs. Subsequently, nab-paclitaxel was infused, and upon completion, the erythematous macules on the limbs faded. The patient was then rechallenged with a slow infusion of camrelizumab, which was well-tolerated without discomfort or a drop in blood pressure. The patient did not report significant discomfort. Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1537205"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of parotid gland tumors using a ternary classification model based on ultrasound radiomics.","authors":"Xiaoling Liu, Weihan Xiao, Chen Yang, Zhihua Wang, Dong Tian, Gang Wang, Xiachuan Qin","doi":"10.3389/fonc.2025.1485393","DOIUrl":"10.3389/fonc.2025.1485393","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the diagnostic value of two-step ultrasound radiomics models in distinguishing parotid malignancies from pleomorphic adenomas (PAs) and Warthin's tumors (WTs).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients who underwent parotidectomy at our institution between January 2015 and December 2022. Radiomics features were extracted from two-dimensional (2D) ultrasound images using 3D Slicer. Feature selection was performed using the Mann-Whitney <i>U</i> test and seven additional selection methods. Two-step LASSO-BNB and voting ensemble learning modeling algorithm with recursive feature elimination feature selection method (RFE-Voting) models were then applied for classification. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), and internal validation was conducted through fivefold cross-validation.</p><p><strong>Results: </strong>A total of 336 patients were included in the study, comprising 73 with malignant tumors and 263 with benign lesions (118 WT and 145 PA). The LASSO-NB model demonstrated excellent performance in distinguishing between benign and malignant parotid lesions, achieving an AUC of 0.910 (95% CI, 0.907-0.914), with an accuracy of 86.8%, sensitivity of 92.5%, and specificity of 66.7%, significantly outperforming experienced sonographers (accuracy of 61.90%). The RFE-Voting model also showed outstanding performance in differentiating PA from WT, with an AUC of 0.962 (95% CI, 0.959-0.963), accuracy of 83.0%, sensitivity of 84.0%, and specificity of 92.1%, exceeding the diagnostic capability of experienced sonographers (accuracy of 65.39%).</p><p><strong>Conclusion: </strong>The two-step LASSO-BNB and RFE-Voting models based on ultrasound imaging performed well in distinguishing glandular malignant tumors from PA and WT and have good predictive capabilities, which can provide more useful information for non-invasive differentiation of parotid gland tumors before surgery.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1485393"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating multimodal features to predict the malignancy of pulmonary ground-glass nodules: a multicenter prospective model development and validation study.","authors":"Yuanhui Wei, Wei Zhao, Zhen Wu, Nannan Guo, Miaoyu Wang, Hang Yu, Zirui Wang, Wenjia Shi, Xiuqing Ma, Chunsun Li, Jiabo Ren, Yue Yin, Shangshu Liu, Zhen Yang, Liang-An Chen","doi":"10.3389/fonc.2025.1547816","DOIUrl":"10.3389/fonc.2025.1547816","url":null,"abstract":"<p><strong>Background: </strong>There is a clinical need for accurate noninvasive evaluation of the malignancy of pulmonary ground-glass nodules (GGNs) to reduce risks of overdiagnosis and overtreatment. This study aimed to develop and validate a clinic-biomarker-combined deep radiomic model for the prediction of GGN malignancy.</p><p><strong>Materials and methods: </strong>This study recruited patients with GGNs from seven medical centers across five cities in China. The participants included in this study were divided into the training-validation and the test groups on the basis of the centers from which they were recruited. The malignancy of GGNs was determined based on pathological results. Clinical, radiological, and biomarker features with significant differences were used to establish predictive models. Six types of models based on different features were developed on the training-validation group: clinical-radiological (CR), biomarker-combined CR (B-CR), deep radiomic (DR), clinic-combined DR (C-DR), biomarker-combined DR (B-DR), and clinic-biomarker-combined DR (CB-DR) models. The models were then evaluated on the test group for discrimination, calibration, and clinical utility.</p><p><strong>Results: </strong>A total of 501 participants with 571 GGNs were included in the study. Four hundred and seven participants with 454 GGNs were assigned to the training-validation group, whereas 94 participants with 117 GGNs were assigned to the test group. Significant differences were observed in sex, smoking history, triosephosphate isomerase-1 and microRNA-206 between patients with and without malignant GGNs. And size, location, and lobulation were significantly different between benign and malignant GGNs. Among all the models, the CB-DR model achieved the highest performance in classifying GGNs, with an AUC of 0.90 (95% CI: 0.81-0.97). At the optimal cutoff, the corresponding accuracy, sensitivity, and specificity were 0.89 (95% CI: 0.83-0.94), 0.90 (95% CI: 0.84-0.96), and 0.82 (95% CI: 0.62-1.00), respectively. Furthermore, malignancy evaluation based on the CB-DR model would have reduced overtreatment for 82.4% (14/17) of benign GGNs and enabled timely interventions for 90.0% (90/100) of malignant GGNs.</p><p><strong>Conclusion: </strong>The CB-DR model developed in this study exhibited satisfactory performance in predicting the malignancy of GGNs and holds potential as a valuable tool for aiding clinical decision-making in GGN management.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1547816"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential role of BCL-2 inhibition in amyloidosis and plasma cell leukemia.","authors":"Grigorios Alvanidis, Dimitrios Kotsos, Christina Frouzaki, Amalia Fola, Evdoxia Hatjiharissi","doi":"10.3389/fonc.2025.1549891","DOIUrl":"10.3389/fonc.2025.1549891","url":null,"abstract":"<p><p>Plasma cell neoplasms include a spectrum of disorders, such as plasma cell leukemia (PCL) and light chain (AL) amyloidosis, all associated with poor prognosis and limited therapeutic options. Venetoclax is the first-in-class B-cell lymphoma 2 (BCL-2) inhibitor and triggers apoptosis selectively in cells reliant on the BCL-2 pathway for survival. Randomized clinical trials have established the anti-tumor activity and efficacy of venetoclax in selected patients with hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). At the same time, recent studies suggest its potential application in rare plasma cell dyscrasias. Preliminary results from case reports and a small cohort of patients indicate that venetoclax may benefit patients with PCL. Regimens incorporating venetoclax have also demonstrated promising outcomes in patients with AL amyloidosis, particularly those with translocation (11;14). This review analyzes new data on venetoclax in AL amyloidosis and PCL and highlights the increasing significance of BCL-2 inhibition in plasma cell neoplasms beyond MM.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1549891"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-lymph cross-plane projection reveals spatial relationship features: a ResNet-CBAM model for prognostic prediction in esophageal cancer.","authors":"Jiayang Xu, Chen Huang, Qianshun Chen, Jieyang Wang, Yuyu Lin, Wei Tang, Wei Shen, Xunyu Xu","doi":"10.3389/fonc.2025.1567238","DOIUrl":"10.3389/fonc.2025.1567238","url":null,"abstract":"<p><strong>Background: </strong>Prognostic models for esophageal cancer based on contrast-enhanced chest CT can aid thoracic surgeons in developing personalized treatment plans to optimize patient outcomes. However, the extensive lymphatic drainage and early lymph node metastasis of the esophagus present significant challenges in extracting and analyzing meaningful lymph node characteristics. Previous studies have primarily focused on tumor and lymph node features separately, overlooking spatial correlations such as position, direction, and volumetric ratio.</p><p><strong>Methods: </strong>A total of 285 patients who underwent radical resection surgery at Fujian Provincial Hospital from 2018 to 2022 were retrospectively analyzed. This study introduced a tumor-lymph node projection plane, created by projecting lymph node ROIs onto the tumor ROI plane. A ResNet-CBAM model, integrating a residual convolutional neural network with a CBAM attention module, was employed for feature extraction and survival prediction. The PJ group utilized tumor-lymph node projection planes as training data, while the TM and ZC groups utilized tumor ROIs and concatenated images of tumor and lymph node ROIs, respectively, as controls. Additional comparisons were made with traditional machine learning models (support vector machines, logistic regression, and K-nearest neighbors). Survival outcomes (median, 1-year, 3-year, 5-year) were used as target labels to evaluate model performance in distinguishing high-risk patients and predicting both short- and long-term survival.</p><p><strong>Results: </strong>In the PJ group, the ResNet-CBAM model achieved accuracy rates of 0.766, 0.981, 0.883, and 0.778 for predicting median, 1-year, 3-year, and 5-year survival, respectively. Its corresponding AUC values for 1-, 3-, and 5-year survival were 0.992, 0.913, and 0.835. Kaplan-Meier survival analysis revealed significant differences between high- and low-risk groups identified by the model. The ResNet-CBAM model outperformed those in the TM and ZC groups in distinguishing high-risk patients and predicting both short- and long-term survival. Compared to machine learning models, it demonstrated superior performance in long-term survival prediction.</p><p><strong>Conclusion: </strong>The ResNet-CBAM model trained on tumor-lymph projection planes effectively distinguished high-risk esophageal cancer patients and outperformed traditional models in predicting survival outcomes. By capturing spatial relationships between tumors and lymph nodes, it demonstrated enhanced predictive efficiency.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1567238"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A viral infection prediction model for patients with r/r B-cell malignancies after CAR-T therapy: a retrospective analysis.","authors":"Shujing Guo, Jile Liu, Bing Wang, Xiaomei Zhang, Yifan Zhao, Jianmei Xu, Xinping Cao, Mohan Zhao, Xia Xiao, Mingfeng Zhao","doi":"10.3389/fonc.2025.1549809","DOIUrl":"10.3389/fonc.2025.1549809","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin lymphoma (B-NHL) patients has shown promising effects, but side effects such as viral infections have been observed.</p><p><strong>Methods: </strong>A total of 45 patients with r/r B-ALL and r/r B-NHL were included in this retrospective study. Patient demographics were recorded, with the primary endpoint being viral infection within 3 months post CAR-T treatment. Univariate and multivariate logistic regression analyses and least absolute shrinkage and selection operator (LASSO) regression analysis were used to analyze independent factors. The patients were divided into a training cohort of 28 and a validation cohort of 17 to construct a prediction model based on determined independent factors. The model's discrimination and calibration were assessed using the receiver operating characteristic curve (ROC), calibration plot, and decision curve analysis (DCA curve).</p><p><strong>Results: </strong>The univariate and multivariate logistic regression analyses of the 43 patients showed that low baseline lymphocyte ratio was an independent risk factor and using granulocyte colony-stimulating factor (G-CSF) early was a protective factor for viral infection after CAR-T therapy in patients with B-ALL and B-NHL. Based on that, the area under the ROC curve (AUC) of the training cohort and validation cohort was 0.935 (95% CI 0.837-1.000) and 0.869 (95%CI 0.696-1.000), respectively, showing excellent predictive value.</p><p><strong>Conclusions: </strong>We established a nomogram to predict the factors' influence on viral infection after CAR-T therapy and found that the ratio of baseline lymphocytes and using G-CSF early or lately were able to predict viral infection after CAR-T therapy in r/r B-ALL and B-NHL.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1549809"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing alternative splicing events as potential targets for the design of diagnostic and therapeutic tools in PCa.","authors":"Nancy Martínez-Montiel, José de Jesús Vite-Arciniega, Nora Hilda Rosas-Murrieta, Rebeca D Martínez-Contreras","doi":"10.3389/fonc.2025.1520985","DOIUrl":"10.3389/fonc.2025.1520985","url":null,"abstract":"<p><p>Alternative splicing is a key mechanism responsible for protein diversity in eukaryotes. Even when the relevance of this process was initially overlooked, it is now clear that splicing decisions have a strong impact on the physiology of organisms. Moreover, aberrant splicing products have been clearly related to different diseases, including cancer. Deregulation of splicing factors or mutations at the immature mRNA level could be responsible of generating these aberrant products that are involved in cell biology processes, including migration, angiogenesis, differentiation, cell cycle, DNA repair and so on. For this reason, alternative splicing is now considered a hallmark of cancer. Prostate cancer is one of the most frequently diagnosed types of cancer and some of the leading global cause of cancer death men. Prostate cancer shows an important incidence in the developing world, while the mortality rate is growing because of limited medical infrastructure and awareness. Here, we present some of the key alternative splicing events related to prostate cancer and even when the exact role of these isoforms in the development of the disease has not been fully understood, we believe that the correction of these aberrant splicing events represents an attractive target for the design of innovative diagnostic and therapeutic tools.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1520985"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation of regional nodal irradiation fields in pT1-2N1 breast cancer patients after breast conserving surgery: retrospective real-world clinical experience.","authors":"Ji Hyun Hong, Jin-Ho Song, Kyu-Hye Choi, Shin Woo Kim, Woo-Chan Park, Jieun Lee, Ahwon Lee, Jun Kang, Byung-Ock Choi","doi":"10.3389/fonc.2025.1484190","DOIUrl":"10.3389/fonc.2025.1484190","url":null,"abstract":"<p><strong>Purpose: </strong>Regional nodal irradiation (RNI) in pN1 patients with one to three positive axillary lymph node breast cancers remains controversial. This study aimed to evaluate the impact of RNI in patients with pT1-2N1 breast cancer who underwent radiotherapy after breast-conserving surgery (BCS), focusing on risk stratification and defining the extent of RNI as axillary lymph node levels I and II.</p><p><strong>Methods: </strong>Female patients with pT1-2N1 breast cancer after BCS with axillary lymph node dissection or sentinel lymph node biopsy who were treated with radiotherapy between 2009 and 2021 were identified. Radiotherapy included either whole-breast irradiation (WBI) alone or WBI with RNI to axillary levels I and II. Patients were categorized into three risk groups based on pathological T stage, number of positive lymph nodes, and immunohistochemical classification.</p><p><strong>Results: </strong>A total of 464 patients were analyzed, with a median follow-up of 68.5 months. A total of 212 (45.7%) patients received WBI alone, and 252 (54.3%) received WBI with RNI. Overall, RNI did not significantly improve disease-free survival (DFS) (p = 0.317), locoregional recurrence-free survival (LRRFS) (p = 0.321), distant metastasis-free survival (DMFS) (p = 0.452), or overall survival (OS) (p = 0.721). However, RNI demonstrated a significant benefit in terms of LRRFS (p = 0.014) in the high-risk group. Case-control matched analysis showed robust benefits in DFS (p = 0.020), LRRFS (p = 0.030), and marginal improvement in DMFS (p = 0.066) in the high-risk group. The toxicities were comparable between WBI alone and WBI with RNI.</p><p><strong>Conclusions: </strong>RNI omission may be considered in low-risk patients with pT1 and one positive lymph node. High-risk patients with pT2, two to three lymph nodes, or triple-negative breast cancer may benefit from RNI. De-escalation of the RNI extent might be considered for non-inferior survival outcomes with comparable toxicities.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1484190"},"PeriodicalIF":3.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}